These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33225788)

  • 1. The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.
    Meng G; Wang Y; Wang J; Wang Z
    Leuk Lymphoma; 2021 Apr; 62(4):854-860. PubMed ID: 33225788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.
    Pi Y; Wang J; Zhou H; Ye X; Sun X; Liu L; Pan X; Wang Z
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3033-3041. PubMed ID: 35852619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
    Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
    Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis].
    Wang Y; Huang W; Wei N; Zeng X; Zhang J; Wang J; Wu L; Fu L; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):901-4. PubMed ID: 25339326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH.
    Meng G; Wang J; Cui T; Wang Z
    Ann Hematol; 2022 Oct; 101(10):2289-2296. PubMed ID: 35999388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.
    Wang Y; Huang W; Hu L; Cen X; Li L; Wang J; Shen J; Wei N; Wang Z
    Blood; 2015 Nov; 126(19):2186-92. PubMed ID: 26289641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    He Y; Gao Y; Ping L; He H; Huang C; Bai B; Wang X; Li Z; Cai Q; Huang Y; Pan X; Zeng W; Liu Y; Huang H
    J Cancer Res Clin Oncol; 2023 May; 149(5):2017-2027. PubMed ID: 35809114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
    Chen L; Wang J; Wang Z
    Ann Hematol; 2022 Nov; 101(11):2461-2470. PubMed ID: 36094533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical characteristics and prognosis of lymphoma-associated hemophagocytic syndrome].
    Zhao AL; Li M; Li LF; Gan XA; Wang J; Li H; Shen K; Yang YF; Niu T
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2173-2180. PubMed ID: 35872581
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: a systematic review of 63 patients reported in the literature.
    Ou W; Zhao Y; Wei A; Ma H; Zhang L; Lian H; Zhang Q; Wang D; Li Z; Wang T; Zhang R
    Clin Exp Med; 2023 Dec; 23(8):4575-4583. PubMed ID: 37840116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation.
    Zou H; He L; Hue Z; Liu M; Yao S; Zhu Y; Wang Z; Wang Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8521-8533. PubMed ID: 37093345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis.
    Yuan S; Wang Y; Luo H; Jiang Z; Qiao B; Jiang Y; Hu Y; Cheng Y; Chen X; Gong W; Huang Y; Zhao W; Luo D; Liu B; Su H; Zhou J; Song S
    Br J Haematol; 2020 Apr; 189(1):72-83. PubMed ID: 31960419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.
    Wang J; Wang D; Zhang Q; Duan L; Tian T; Zhang X; Li J; Qiu H
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):859-71. PubMed ID: 26666755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.
    Zhou L; Liu Y; Wen Z; Yang S; Li M; Zhu Q; Qiu S; Gao Y; Wang H; Yuan Y; Zhang H; Chen C; Zeng W; Guan Z; Pan X
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3063-3074. PubMed ID: 32617699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Interleukin-10 Levels Are Associated with Low Platelet Count and Poor Prognosis in 90 Adult Patients with Hemophagocytic Lymphohistiocytosis.
    Hao L; Ren J; Zhu Y; Ma Y; Pan J; Yang L
    Int Arch Allergy Immunol; 2023; 184(4):400-408. PubMed ID: 36634629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.